Treatment of C. difficile Infection in Immunocompromised Patients

This protocol covers Clostridioides difficile infection (CDI) arising in patients with an immunocompromised state. Immune compromise is a key clinical modifier that directly informs the choice of first-line therapy.

Current evidence-based guidelines identify specific antibiotic agents as the recommended first-line choice for CDI in immunocompromised patients. Agent selection, supporting criteria, and the full treatment algorithm are detailed in the structured protocol.